C6orf192 Inhibitors
Chemical inhibitors of C6orf192 include a variety of compounds that target vesicular transport mechanisms, which are central to the function of this protein. Reserpine and Tetrabenazine are VMAT inhibitors that can lead to the functional inhibition of C6orf192 by blocking monoamine neurotransmitter uptake into synaptic vesicles, reducing the vesicular storage and transport capacity. Similarly, Methyldopa alters the dopaminergic system and indirectly affects the vesicular storage and release mechanisms, potentially inhibiting the transport functions where C6orf192 is active. Amiodarone, by changing the properties of lipid membranes, can affect vesicle formation and transport processes, disrupting the function of proteins like C6orf192 involved in these pathways. Chlorpromazine, which impacts cellular trafficking and the storage of monoamines within vesicles, can inhibit vesicular transport systems and disrupt the functional processes of C6orf192.
Additionally, inhibitors such as Flunarizine and Verapamil can block calcium channels, leading to the inhibition of calcium-dependent exocytosis and endocytosis processes, thereby affecting vesicular trafficking activities that C6orf192 is associated with. Baclofen, a GABA_B receptor agonist, indirectly inhibits voltage-gated calcium channels and may affect vesicular trafficking pathways, thereby potentially inhibiting C6orf192's function. Calcium channel blockers like Nicardipine, Diltiazem, and Nimodipine can interfere with calcium signaling that regulates vesicular transport and release, processes where C6orf192 might play a role. By inhibiting these channels, they could disrupt calcium-dependent secretory pathways, potentially inhibiting vesicular transport functions that C6orf192 could facilitate. Each of these chemicals, through their distinct modes of action, can contribute to the functional inhibition of C6orf192 by targeting the specific biochemical or cellular pathways that the protein is known to be part of or interact with in the context of vesicular transport.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Reserpine | 50-55-5 | sc-203370 sc-203370A | 1 g 5 g | $137.00 $414.00 | 1 | |
Reserpine binds to and inhibits vesicular monoamine transporters (VMATs), which are crucial for monoamine neurotransmitter storage in synaptic vesicles. C6orf192 is postulated to be involved in similar vesicular transport mechanisms. By inhibiting VMATs, reserpine could decrease the vesicular storage and transport functions where C6orf192 is active. | ||||||
Tetrabenazine | 58-46-8 | sc-204338 sc-204338A | 10 mg 50 mg | $168.00 $721.00 | ||
Tetrabenazine, like reserpine, is a VMAT inhibitor. It depletes monoamine neurotransmitters from vesicles by inhibiting their uptake. This action could inhibit the vesicular transport systems where C6orf192 operates by limiting the availability of vesicular transporters and storage capacity. | ||||||
Ketanserin | 74050-98-9 | sc-279249 | 1 g | $700.00 | ||
Ketanserin is a receptor antagonist that may lead to the inhibition of intracellular pathways relying on serotonin signaling, possibly affecting vesicular trafficking processes in which C6orf192 is implicated due to its suspected role in vesicular transport. | ||||||
Amiodarone | 1951-25-3 | sc-480089 | 5 g | $318.00 | ||
Amiodarone has multiple cellular effects, including the alteration of lipid membranes. By changing membrane properties, it could affect vesicle formation and transport processes, thereby inhibiting the function of proteins like C6orf192 involved in these pathways. | ||||||
Chlorpromazine | 50-53-3 | sc-357313 sc-357313A | 5 g 25 g | $61.00 $110.00 | 21 | |
Chlorpromazine has been shown to affect cellular trafficking and the storage of monoamines within vesicles. This could inhibit vesicular transport systems and potentially disrupt the functional processes of C6orf192. | ||||||
Flunarizine | 52468-60-7 | sc-337841 | 5 g | $560.00 | ||
Flunarizine can block calcium channels and may therefore inhibit calcium-dependent exocytosis and endocytosis processes, which could affect the vesicular trafficking activities that C6orf192 is associated with. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Verapamil, a calcium channel blocker, may inhibit calcium-dependent vesicle fusion and trafficking. Given C6orf192's putative role in vesicular transport, verapamil could thus functionally inhibit C6orf192 by disrupting these processes. | ||||||
(±)-Baclofen | 1134-47-0 | sc-200464 sc-200464A | 1 g 5 g | $56.00 $258.00 | ||
Baclofen is a GABA_B receptor agonist, which indirectly inhibits voltage-gated calcium channels. This inhibition may affect vesicular trafficking pathways, thereby potentially inhibiting the function of C6orf192. | ||||||
Nicardipine hydrochloride | 54527-84-3 | sc-202731 sc-202731A | 1 g 5 g | $33.00 $83.00 | 5 | |
Nicardipine blocks L-type calcium channels. By inhibiting these channels, it could interfere with calcium signaling that regulates vesicular transport and release, processes where C6orf192 might play a role. | ||||||
Diltiazem | 42399-41-7 | sc-204726 sc-204726A | 1 g 5 g | $209.00 $464.00 | 4 | |
Diltiazem inhibits calcium influx through L-type calcium channels, which may disrupt calcium-dependent secretory pathways, potentially inhibiting vesicular transport functions that C6orf192 could facilitate. | ||||||